| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC1535 | Covidcil-19 | Novel viral propagation inhibitor, binding to the revised attenuator hairpin structure of the SARS-CoV-2 frameshifting element (FSE), stabilizing the hairpin's folded state and reducing frameshifting efficiency in cells |
|
| DCC1536 | Cp-195543 | Potent and selective leukotriene B4 antagonist |
|
| DCC1537 | Cp-281384 | Novel potent and selective p38alpha inhibitor |
|
| DCC1538 | Cp-320626 | Inhibitor of glycogen phosphorylase; Antidiabetic |
|
| DCC1539 | Cp-339818 | Inhibitor of Kv1.3 potassium ion channels |
|
| DCC1540 | Cp-457920 | Novel selective α5 GABA A receptor agonist |
|
| DCC1541 | Cp-615003 | Novel Mdr1 P-glycoprotein substrate |
|
| DCC1542 | Cp-868388 | Potent PPARα agonist with a Ki of 10.8 nM |
|
| DCC1543 | Cp-94707 | Novel nonnucleoside reverse transcriptase inhibitor (NNRTI) |
|
| DCC1544 | Cpd118 | Novel inhibitor of against human liver FBPase (IC50, 0.029±0.006 μM) and high selectivity relative to the other six AMP-binding enzymes, producing significant glucose-lowering effects on both type 2 diabetic KKAy mice and ZDF rats |
|
| DCC1545 | Cpd7 Hydrochloride | Novel non-RBD binding modulator to inhibit SARS-CoV-2 by prohibiting the conformational change of the spike (S) protein |
|
| DCC1546 | Cpfikk-in-4b | Novel potent inhibitor of CpFIKK catalytic activity |
|
| DCC1547 | Cpi098 | Novel selective inhibitor of the CREB binding protein (CBP) |
|
| DCC1548 | Cpi-7c | Unique inhibitor of MDM2, inhibiting MDM2-p53 interaction and promoting MDM2 degradation |
|
| DCC1549 | Cpimpdh-in-c64 | Novel CpIMPDH inhibitor |
|
| DCC1550 | Cpp11g | Novel selective NADPH oxidase 2 (Nox2) inhibitor, attenuating endothelial cell inflammation and vessel dysfunction and restoring mouse hind-limb flow |
|
| DCC1551 | Cpp11h | Novel selective NADPH oxidase 2 (Nox2) inhibitor, attenuating endothelial cell inflammation and vessel dysfunction and restoring mouse hind-limb flow |
|
| DCC1552 | Cppz-2c | Novel positive allosteric modulator (PAM) of metabotropic glutamate receptor 5 (mGlu5) |
|
| DCC1553 | Cpr005231 | Novel inhibitor of death-associated protein kinase 1 (DAPK1), also inhibiting VEGF-receptor 2 and tyrosine-protein kinase SRC |
|
| DCC1554 | cpu-0213 | Novel endothelin receptor antagonist, suppressing the upregulation of matrix metalloproteinases and connexin 43 in hyperthyroid myocardium |
|
| DCC1555 | Cpu-l1 | Novel potent and selective fluorescent inhibitor of glutaminase (GLS1) |
|
| DCC1556 | Cpx-351 | Liposomal-encapsulated combination of daunorubicin and cytarabine for the treatment of newly diagnosed tAML or AML with myelodysplasia-related changes (AML-MRCs) |
|
| DCC1557 | Cqmu151 | Novel RORγt inhibitor, suppressing Th17 cell differentiation, reducing the severity of experimental autoimmune disease models such as EAU, EAE, and type 1 diabetes |
|
| DCC1558 | Cqmu152 | Novel RORγt inhibitor, suppressing Th17 cell differentiation, reducing the severity of experimental autoimmune disease models such as EAU, EAE, and type 1 diabetes |
|
| DCC1559 | Cqs1000 | Novel NIR-II probe, noninvasively and dynamically visualizing and monitoring many physiological and pathological conditions of circulatory systems, including lymphatic drainage and routing, angiogenesis of tumor, and vascular deformity such as arterial th |
|
| DCC1560 | Cra-19156 | Novel potent HDAC8 inhibitor |
|
| DCC1561 | Cranad-102 | Novel probe for selectively detecting sAβ species in Alzheimer's disease (AD) |
|
| DCC1562 | Cranad-5 | Foster Resonance Energy Transfer (FRET) pair for Aβ40 aggregates |
|
| DCC1563 | Creatine Phosphate Disodium Hydrate | Substrate for the assay of creatine kinase, providing a quick source of energy for muscle fibers to contract when they need an initial burst of energy |
|
| DCC1564 | Creb Inhibitor 666-15 | Novel potent and cell-permeable inhibitor of cAMP-response element binding protein (CREB) |
|
